Septic shock after treatment of pyoderma gangrenosum with infliximab.
Wölbing
Florian
F
Fierlbeck
Gerhard
G
Hötzenecker
Wolfram
W
Schaller
Martin
M
Röcken
Martin
M
D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D003879:Dermatologic Agents / Q000009:adverse effects*; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D017511:Pyoderma Gangrenosum / Q000188:drug therapy*; D012772:Shock, Septic / Q000139:chemically induced*
D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D000069285:Infliximab